## **RLS Community Speaks Out**



Restless Legs Syndrome Foundation, Inc. is dedicated to improving the lives of the men, women and children who live with this often devastating disease. The organization's goals are to increase awareness, to improve treatments and, through research, to find a cure for RLS.

#### 2018 - 2019 Board of Directors

Lewis Phelps, Chair Pasadena, CA

Linda R. Secretan, Secretary Eagle, ID

Ronald W. Barrett, PhD, *Treasurer* Saratoga, CA

Jacquelyn (Jacci) Bainbridge, PharmD Englewood, CO

**Steve McCann** Atlantic Beach, FL

**Greg Oberland** Whitefish Bay, WI

**Shalini Paruthi, MD** St. Louis, MO

**Carla Rahn Phillips** *Wimberley, TX* 

**Paul Rochester** *Hillsborough, CA* 

Ellen Spoehr Chadds Ford, PA

**Robert (Bob) Waterman, Jr., (Chair Emeritus)** Hillsborough, CA

#### 2018 - 2019 RLS Foundation Scientific and Medical Advisory Board

Christopher J. Earley, MB, BCh, PhD, FRCPI Chair Baltimore, MD

**Philip Becker, MD** Dallas, TX

Marie-Françoise Chesselet, MD, PhD Los Angeles, CA

Stefan Clemens, PhD, HdR Greenville, NC

James R. Connor, PhD Hershey, PA

Jeffery S. Durmer, MD, PhD Johns Creek, GA

**Sergi Ferré, MD, PhD** *Baltimore, MD* 

Jennifer G. Hensley, EdD, CNM, WHNP Nashville, TN

**Byron C. Jones, PhD** *Memphis, TN* 

Brian B. Koo, MD West Haven, CT

Mauro Manconi, MD, PhD Lugano, Switzerland Mark P. Mattson, PhD Baltimore, MD

**Emmanuel Mignot, MD, PhD** *Palo Alto, CA* 

William Ondo, MD Houston, TX

Michael H. Silber, MB, ChB Rochester, MN

**Lynn Marie Trotti, MD, MSc** *Atlanta, GA* 

George Uhl, MD, PhD Albuquerque, NM

Arthur S. Walters, MD Nashville, TN

John W. Winkelman, MD, PhD Boston, MA

The Restless Legs Syndrome Foundation Board of Directors held meetings on:

12/19/18 Telephonic

2/14/19 Telephonic


4/9/19 Telephonic

7/9/19 Telephonic

## 2019 Highlights | From the Chairman of the Board

Like many of you, over the years I have faced ignorance, impatience, and downright hostility from doctors and others as I tried to explain to them the maddening condition we all share: restless legs syndrome. We suffer sleepless nights and pain, knowing something is wrong, yet we were faced with ignorance or (worse) with mis-diagnoses and poor treatments that did nothing or even made life worse.

But because of the work of the Restless Legs Syndrome Foundation, we now live in a world where information is available to patients and doctors alike. The Foundation's webinar series, aimed at health care professionals, offers continuing education on the nature of the disease and medical interventions of value. The Foundation's website offers an informed, science-based repository of information available to patients, their families, and their doctors. Support Groups, with leaders selected and trained by the Foundation, serve the emotional needs of people dealing with the disease. Foundation-certified Quality Care Centers located in the nation's top medical facilities offer state of the art care and management to their patients. A locator service on the Foundation's website directs people to physicians known to be skilled at RLS treatment and sensitive to the toll the disease can take on one's life and work.



Lewis Phelps Chair, RLS Foundation Board of Directors

We hold national meetings – one in La Jolla, California last year and an upcoming one in Baltimore, Maryland – to provide a forum where leaders in the field can meet with and share knowledge about RLS with our members.

The Foundation also supports the nation's only RLS research grant program, providing startup assistance to researchers looking for underlying causes for the disease. Over the years, we have provided over \$1.8 million to 47 grantees, pushing the boundaries of knowledge. Our research funding has also supported data collection efforts, assembling information that can be mined for new treatments and perhaps even a cure.

As noted in last year's Annual Report, the Foundation has been active in Washington DC to share information with Congress and regulators about the disease. The Foundation's presence in DC has been very important in enhancing visibility of the name and the disease. This gives us a fighting chance for competitive grant money when measured up against heart disease, cancer, and neurological conditions like Alzheimer's. This year at least three of our grantees have been awarded additional grants from the National Institute of Health to further their important research. In the midst of panic about wide-spread abuse of opiates, the Foundation has engaged its members and professionals to ensure that federal regulations do not overburden or prohibit access to medications for those of us with RLS who depend on long-term, smaller-dose prescriptions. With your help, we will continue this work, while simultaneously urging the National Institutes of Health and the Department of Defense to increase funds available for basic and applied research on RLS. The RLS Foundation's presence in Washington, DC, has been very important in enhancing visibility of the name and the disease. This gives us a fighting chance for competitive grant money when measured up against heart disease, cancer, and neurological conditions like Alzheimer's. Further work is needed. Another visit to Washington DC is planned in February to address the possibility of giving RLS higher visibility on grant-supported initiatives

The Foundation is truly lucky to have a deeply engaged set of volunteer leaders – Board of Directors members, Science and Medical Advisory Board members, Support Group leaders, and individuals – who give their time and energy to meet our needs. Our small, hard-working staff in national headquarters oversees the daily work of keeping the Foundation running smoothly. And all of us benefit from the generosity of a committed set of supporters and major donors who provide inspiration and means for everything we do. But it is you, our members, drawn from a pool of quiet, heroic sufferers of an often-discouraging disease, who are our lifeblood and inspiration. Thank you for all you do to support and inspire us.

This is my final year as Chair of the Foundation's Board of Directors. Personal challenges arising from serious injuries I sustained have meant that I have had to lean on others even more heavily than in the past. I have thanked each of them personally, but particularly want to mention with gratitude the way Ron Barrett stepped up to provide leadership when I was unable to do so. As always, Karla Dzienkowski, the Foundation's Executive Director, was ever on the case. As Board leadership shifts to Carla Rahn Phillips – someone I have known and admired for decades – I want to thank every member and supporter of the Foundation for all you have done and will do in the future. Let's keep working until we have this disease licked!

Lew Phelps Chairman of the Board

### 2019 Highlights | Find a Cure

## **Researchers Develop Self-Assessment Tool for RLS Severity**

A new tool to evaluate RLS symptom severity has been developed that may improve the ability of clinicians to provide high-quality care to patients, and expand opportunities for researchers to conduct large studies.

An international team of researchers has developed a selfadministered version of the International Restless Legs Syndrome Severity Scale, or IRLS, which has been used by clinicians and researchers worldwide since 2013. In the IRLS, an individual's RLS severity is rated on a scale from "very severe" to "none" based on a patient questionnaire.

This scale helps clinicians monitor a patient's symptoms, plan treatment and measure outcomes; and is used widely in research. Its use is limited, however, by the need for a clinician familiar with the scale to administer it to the patient.

To overcome this limitation, the International Restless Legs Syndrome Study Group (IRLSSG) has developed a selfadministered version, called the sIRLS. In a recent study published in *Sleep Medicine*, a team of IRLSSG researchers validated its effectiveness and reliability.

"Overall, we showed that the self-administered scale – the sIRLS – is a reliable, valid and precise instrument, as good as the clinician-administered scale," says Denise Sharon, MD, PhD, of Tulane University School of Medicine, who led the study. "The sIRLS can be successfully and effectively used for research and in the clinical practice to evaluate RLS symptom severity and the quality of care of RLS patients."

Since patients can take the sIRLS without assistance – in the clinic, by mail or online – it offers an economical option that can be used by clinicians who are not familiar with administering the IRLS. It can also be used by researchers who are conducting large, epidemiological studies when the cost of a reliable, clinician-administered scale would be prohibitive. Both versions are designed for patients who have already been diagnosed with RLS.

The sIRLS has the same structure and questions as the IRLS, but the wording is tailored for use by patients rather than clinicians. The researchers consulted with members and staff of the RLS Foundation to develop this more consumer-friendly language.

"Many RLS Foundation members helped us with this task," says Dr. Sharon. "We circulated versions of these instructions, and RLS Foundation members took the time to review the wording, complete the test and give us very important feedback."

In both tests, patients complete a questionnaire in which they rate 11 aspects of their RLS symptoms over the past week, using a five-point scale. For example, questions ask how often they have symptoms, and how RLS affects their ability to carry out their daily affairs.

To determine if the sIRLS could successfully be taken without a healthcare professional present, the researchers recruited 173 RLS patients from eight research centers in four countries, who took both versions of the test.

In their findings, the researchers note that while both scales are effective and reliable, one version should be used consistently when comparing assessments taken at different times. The sIRLS currently is available only in English.

The 21 co-authors of the study included several members of the RLS Foundation Scientific and Medical Advisory Board: Arthur S. Walters, MD; Lynn Marie Trotti, MD, MSc; and Jennifer G. Hensley, EdD, CNM, WHNP; as well as former Medical Advisory Board chair Richard P. Allen, PhD.

"I would like to express my gratitude to RLS Foundation members who helped us in developing and studying the sIRLS," Dr. Sharon says. "To all who participated, thank you!"

## 2019 Highlights | Find a Cure

## New Study on How Opioids Work for RLS

The RLS Foundation has awarded a grant of \$36,398 to Sergi Ferré, MD, PhD, of the National Institute on Drug Abuse, for a study to explore how opioid medications work in the brain to relieve RLS symptoms. This research builds on several Foundation-funded studies previously conducted by Dr. Ferré, who is a member of the RLS Foundation Scientific and Medical Advisory Board.

"Dopamine agonists, alpha-2 delta agents and opioids are highly effective in treating RLS," says Christopher J. Earley, MB, ChB, PhD, FRCPI, chair of the Scientific and Medical Advisory Board. "Dr. Ferré's grant is the first to try and understand the biologic elements that may be common to these three classes of drugs that makes them so effective in treating RLS, thus opening the door for future drug development."

Opioid medications act on three types of opioid receptors in the brain. One of these – the mu opioid receptor – is the target of the opioid medications, such as methadone, that are a very effective treatment for severe RLS when used in low total daily doses. RLS is a neurological disease that has a distinctly different underlying neuropathology than that associated with typical pain syndromes. Clinical experience among experts who use opioids to treat severe RLS has not shown the degree of drug misuse, dependency or addiction that is commonly associated with opioid use to treat chronic pain.\*

In the current study, "Elucidating the mechanisms of the therapeutic effects of opioids in RLS," Dr. Ferré's team aims to identify the locations of mu opioid receptors involved in improving RLS symptoms with opioids. With this information, they hope to determine if specific opioid medications could selectively act on these mu opioid receptors, reducing the risk of unwanted side effects.

In previous studies funded by the RLS Foundation, Dr. Ferré's laboratory developed an animal model for RLS using a brain iron-deficient rodent that models the brain iron deficiency that is characteristic of RLS in humans. Their model combines two techniques, optogenetics and microdialysis, to trigger and measure the release of glutamate from brain cells in live animals. The researchers used this model to confirm that brain iron deficiency increases the release of glutamate in the brain area known as striatum; other studies have reported increased glutamate in the RLS brain.

Dr. Ferré's team also validated that several RLS drugs – the dopaminergic drugs pramipexole and ropinirole, and the alpha-2-delta ligand gabapentin – work by counteracting this high release of glutamate. In addition, the researchers pinpointed a subtype of receptor in the brain – the dopamine D4 receptor – as a main target for the effects of the dopaminergic drugs in the striatum, and therefore, as a new target for drug development. In a more recent study, Dr. Ferré's laboratory reported that low levels of receptors of the neurochemical adenosine are responsible for the high levels of glutamate released in the striatum. This finding has led to exploration of drugs that increase adenosine levels in the brain – for example, dipyridamole – as a new treatment approach for RLS. According to Dr. Ferré, the reduced levels of adenosine receptors (specifically, the adenosine A1 receptors) may be the underlying cause of not only restless legs, but also the state of enhanced wakefulness (hyperarousal) experienced by people who have RLS.

In the current study, the researchers will focus on a specific neuron in the striatum, the cholinergic interneuron, which releases the neurotransmitter acetylcholine and has a high number of both adenosine A1 receptors and mu opioid receptors. The researchers hypothesize that in RLS, there are fewer adenosine A1 receptors in these cholinergic interneurons, which therefore become overactive and release more acetylcholine. The researchers also hypothesize that opioids should be able to counteract this by activating mu opioid receptors in the cholinergic interneurons. Dr, Ferré's team will use its animal model to explore these questions.

"If the results of the study confirm our hypotheses, we will have probably found the main mechanism of the therapeutic effect of opioids in RLS," says Dr. Ferré. "Those results would then stimulate the search for opioids with a preferential efficacy for the mu opioid receptors localized in the striatum, in the cholinergic interneurons, which should be absent of unwanted side effects."

The RLS Foundation is grateful for the generosity of individuals whose financial gifts make this work possible, says Executive Director, Karla Dzienkowski. "The Foundation's research grant program is dedicated to find better treatments and, ultimately, a cure for RLS. This study will help us to understand why opioid medications are effective at relieving severe, unrelenting symptoms of restless legs syndrome, which will lead to an improved quality of life for people with RLS," Dzienkowski says.

\*If opioid therapy is a treatment option to manage your RLS symptoms, your healthcare provider will work closely with you to find the dose that manages your symptoms while minimizing side effects of therapy.

## 2019 Highlights | Improve Treatments

## Study Finds Augmentation Drug a Good Candidate for Research

A research study funded by the RLS Foundation suggests that the drug ecopipam may be a potential candidate for treating augmentation in RLS patients.

In a small, exploratory study, some patients who took ecopipam for five weeks experienced relief from augmentation symptoms, and the drug showed minimal side effects. Ecopipam is an investigational drug currently being studied to treat Tourette's syndrome and other conditions.

"Overall, the results are encouraging," says William Ondo, MD, who conducted the study at Houston Methodist Neurological Institute. "While this study was too small and too short in duration to evaluate whether ecopipam is effective in reversing augmentation, it shows that it is a good candidate to explore in larger studies." Dr. Ondo is director of the RLS Quality Care Center at Houston Methodist, and a member of the RLS Foundation Scientific and Medical Advisory Board. Augmentation is a common and serious side effect of RLS treatment with dopaminergic drugs, including carbidopa/levodopa (Sinemet), pramipexole (Mirapex), ropinirole (Requip) and rotigotine (Neupro).

At first, these drugs may be highly effective at controlling RLS symptoms, but over time they can make RLS worse for many patients. Symptoms typically start appearing earlier in the day, increase in intensity, or start affecting the arms and trunk in addition to the legs. An estimated 50–70 percent of people who take dopaminergic drugs for RLS develop augmentation within 10 years.

The current treatment for augmentation is to reduce the dosage of the dopaminergic medication or to stop taking it. Withdrawal can be intense and difficult, and alternate treatment options are limited. "Our hope is that if we can find an effective treatment for augmentation, then some RLS patients may be able to continue taking the dopaminergic drugs, which are highly effective for many patients," says Dr. Ondo. "Our goal is to find a long-term, effective treatment so that RLS patients can enjoy a better quality of life."

## Baseline Data on Opioids Sets the Stage for Long-Term Study

A study on the long-term safety and effectiveness of opioids to treat RLS has gathered baseline data from more than 400 participants. In work funded by the RLS Foundation, a team led by John Winkelman, MD, PhD, has created a national registry of patients who take opioids to manage their RLS, and will follow these patients for at least the next five years.

"The goal is to assess the long-term safety and efficacy of opioids in RLS, which will help patients and their physicians make more informed decisions about their RLS treatment," says Dr. Winkelman, director of the RLS Quality Care Center at Massachusetts General Hospital.

Participants in the study have completed phone interviews and an initial online survey about their RLS symptoms, treatment, medical history, habits and behaviors. Most have now completed six-month follow-up surveys online.

"Our data shows that people who are taking opioids for RLS are similar to the RLS population in general," says Dr. Winkelman. "They are women, are older, and often are able to get good control of their RLS with low total daily doses of opioids. This is not surprising, given what we generally see in our patients."

Here are some highlights of the data:

• Participants are mostly women (60 percent), and their average age is 65.

- About one-third experienced their first RLS symptoms before age 20.
- Over 50% are taking only an opioid medication to manage their RLS.
- Almost half of participants are taking methadone, at an average total daily dose of 10 mg. The next most common opioid medication is oxycodone, at an average total daily dose of 20 mg.
- 40 percent of those taking an opioid report having no RLS or mild RLS symptoms in the previous week; 25 percent still report severe or very severe symptoms.
- Almost half of participants report a lifetime history of depression; many report a lifetime history of anxiety.
- Over three-fourths of participants (77 percent) are considered low risk for opioid abuse, based on a standardized clinical questionnaire.

"It's exciting that we have been able to recruit this many people who are interested in contributing to answering these questions about opioids in RLS," says Dr. Winkelman.

The RLS Foundation is grateful to all who have participated in this study so far. The RLS community has really stepped up to help each other and future generations that will benefit from these findings.

## 2019 Highlights | Improve Treatments

## Methadone May be Less Addictive Than Other Opioids, Study Finds

Scientists at the National Institute on Drug Abuse (NIDA) and their collaborators report that methadone may produce less euphoria than other opioids, suggesting it may hold less risk for abuse or misuse.

In a study led by Sergi Ferré, MD, PhD, and Annabelle Belcher, PhD, published in the *Journal of Clinical Investigation*, researchers conducted experiments using cells in culture, as well as an animal model, to assess the effects of different opioids on the brain. They found that methadone was much less potent than morphine and fentanyl in activating receptors that drive feelings of euphoria.

In the experiments, the scientists examined the response of opioid receptors in cells in the ventral tegmental area (VTA) of the brain. The VTA is a key area involved in the brain's "reward circuit." The researchers found that opioid receptors located in the VTA link with receptors for another neurotransmitter called galanin to form complexes; and that these complexes are less responsive to methadone than to the other opioids.

The researchers also looked at patient data from the RLS Opioid Registry and from a clinical trial for opioid use disorder (opioid addiction). In both studies, significantly fewer patients said they experienced a "high" from taking methadone compared with the other opioids – confirming results of the lab experiments.

"Our work provides very important support for the use of methadone in RLS. These results provide a substantial basis for arguments for its continued availability and use as an opioid treatment with little addictive potential," says Dr. Ferré, who is a member of the RLS Foundation Scientific and Medical Advisory Board. "The results also open a new path to address the discovery of opioids with lower risk of addiction, which already include methadone. Our ongoing studies will identify the mechanism by which methadone does not activate the opioid-galanin receptor complexes, which light up the reward circuitry, to use this as the basis for future drug development. This is the Holy Grail in the search for effective opioids for the treatment of pain and RLS – we want to emulate that," Dr. Ferré says.

Opioid therapy is used to treat RLS when all other options have failed. At low total daily doses, opioids are effective for controlling RLS symptoms in most patients. Methadone and oxycontin are specifically used for RLS because they are longeracting, so a single dose can control symptoms across a span of many hours.

The NIDA findings present a new way for clinicians to distinguish among opioids, according to co-author John Winkelman, MD, PhD. "This study suggests that methadone may be distinctive in that it doesn't activate the euphoric, or rewarding, centers in the brain, and therefore lessens the risk of misuse or abuse. From this perspective, methadone in low doses is not as worrisome as other opioids. However, it is still an opioid and needs to be used only in select patients and carefully in those individuals," says Dr. Winkelman.

RLS patients who may feel stigmatized for taking methadone can find reassurance in these new findings, according to RLS Foundation Executive Director Karla Dzienkowski, "This gives the RLS patient community validation for this treatment, and hope for the future."

## 2019 Highlights | Improve Treatments

## Medical Cannabis and RLS

Jacquelyn Bainbridge, PharmD, FCCP, MSCS; and Mark Buchfuhrer, MD, FRCP(C), FCCP, FAASM

The medical use of cannabis (marijuana) is increasing in the United States. The drug remains illegal under federal law, even though it is legal in 33 states and the District of Columbia. However, a federal spending bill passed in 2014 prohibits the Justice Department from using federal funds to enforce this ban in states with medical marijuana laws.

Medical cannabis is recognized as a legitimate medical application for many conditions. A position statement from the American Academy of Neurology, "Use of Marijuana for Neurological Disorders," outlines the benefits of some form of medical cannabis for conditions such as multiple sclerosis, epilepsy, and others. While RLS is not included in this position paper, many patients with RLS are looking to experiment with medical cannabis to relieve their symptoms when other treatments are unsuccessful, too expensive or cause unwanted side effects.

#### Current treatment for RLS

Current medications that are approved by the US Food and Drug Administration (FDA) for treating RLS include dopaminergic agents and an alpha-2-delta ligand drug. These drugs work by enhancing dopamine activity in the brain (ropinirole (Requip), pramipexole (Mirapex), rotigotine (Neupro patch)); or by modifying calcium channels on nerves (gabapentin enacarbil (Horizant)), which changes the excitability of nerves that carry RLS sensations or pain.

In addition, several drugs approved for treatment of other medical conditions have undergone clinical studies in RLS patients and provide symptom relief when consistently used "off-label." Off-label use is when a medication is used for a disease or medical condition that it is not approved to treat, according to FDA regulations.

#### Medical cannabis in RLS

We are not sure how cannabis works. It may act on cannabinoid receptors in the brain that affect areas involving motor activity, coordination and pain relief by blocking pain receptor pathways.

There are no current studies or clinical trials on the use of medical cannabis in RLS. Though cannabis is not FDA approved to treat RLS, anecdotal evidence from some patients' experiences has shown that it may improve some of the symptoms commonly associated with RLS.

Typically, ingested cannabis (through brownies or cookies, for example) does not seem to benefit RLS very much, while inhaled cannabis (through a cannabis cigarette or vaporizer) works very quickly and effectively. Most people with RLS report that after only a few puffs of a cannabis cigarette or a few inhalations of vaporized medical cannabis, even very severe symptoms are relieved within minutes. The relief does not last long, wearing off after one or two hours, so inhaled cannabis works best for RLS symptoms that occur mainly at bedtime. (Note that smoking cannabis allows for combustibles to be released into the air and may pose a health risk to the patient and bystanders.) Patients have reported that a one-month supply of medical cannabis may last three to four months when used to treat bedtime RLS symptoms.

Cannabis is a complex plant. Of its 489 chemical constituents, 70 are known to be cannabinoids, and the rest are potentially unwanted neuroactive substances that cross the blood-brain barrier. Cannabinoids may cause drug interactions, so patients who take cannabis should consult with their physician or pharmacist to avoid any unwanted interactions with their other medications.

Within cannabis products, tetrahydrocannabinol (THC) is the major psychoactive ingredient (that is, it affects mental processes) that causes individuals to experience a "high." Cannabidiol (CBD) is the major nonpsychoactive component. From a medical standpoint, products high in CBD and low in THC are believed to produce desired effects in the brain, with little or no side effects on mental processes.

Some of the cannabinoids widely consumed are:

- Cannabinoid-rich preparations of cannabis in the herb (plant) or resin form
- Cannabinoid-containing pharmaceutical products containing natural cannabis extracts (Sativex, a GW Pharmaceuticals/ Greenwich Biosciences drug in clinical trials in the United States and approved for use in Canada and other countries)
- Synthetic cannabinoid (dronabinol (Marinol)), tetrahydrocannabinol (THC) or nabilone (Cesamet)

Studies have shown that medical cannabis may reduce pain and muscle spasticity symptoms. These studies found patients were able to tolerate cannabis well without significant side effects. The most common reported side effects of cannabis are dizziness, fatigue, dry mouth and nausea.

Many factors limit the use of medical cannabis to treat RLS. First, no clinical trials have documented its benefits for treating RLS. Second, studies of medical cannabis to treat pain and muscle spasticity were relatively small and conducted over a short period of time, and therefore do not provide information on how a patient would respond to long-term use. Moreover, the long-term side effects or complications of medical cannabis itself are unknown.

Finally, since cannabis is still considered illegal under federal law in the US, it is very difficult for researchers to study its medical use. Very few well-controlled trials of cannabis have been designed because institutions will not allow human consumption due to its federal legal status.

In summary, in addition to federal acceptance of the legality of cannabis, more clinical trials are needed to validate whether medical cannabis would be an effective treatment for RLS.

## 2019 Highlights | Increase Awareness

## Raising Our Voice to Congress: RLS Advocacy Day on Capitol Hill

Thirty members of the RLS community from across the US gathered in Washington, DC, on May 3 for the first RLS Advocacy Day on Capitol Hill.

RLS patients and Foundation staff were joined by Jeffrey Durmer, MD, PhD, a member of the Foundation's Scientific and Medical Advisory Board; and Sandra Katanick, a member of the Board of Directors; for a whirlwind day of meetings with congressional offices. An RLS Foundation delegation also attended meetings on May 2. Over the two days, the Foundation met with staff members of 45 Congressional representatives representing 16 states, including key members of committees that shape health policy.

"Our first advocacy day exceeded everyone's expectations," says Karla Dzienkowski, Executive Director of the RLS Foundation. "This was an exciting opportunity for staff and RLS community members to join forces to advance our goals. We made headway in educating key offices that can champion our legislative agenda."

RLS Advocacy Day took place at the heart of the federal appropriations process, when Congress designates dollars to fund specific areas of the government – and at a time when Congress is engaging in oversight activities to implement key legislation that addresses the opioid epidemic: the Comprehensive Addiction and Recovery Act (CARA), and the SUPPORT for Patients and Communities Act.

The day began with a prep session led by the Health and Medical Counsel of Washington (HMCW). "Most folks don't know what restless legs syndrome is, including people who make decisions at the highest level of government," said Peter Herzog, a legislative associate at HMCW. "That's where decision-makers rely on their staff who focus on these issues, on expert opinion, and on their constituents. RLS patients are both experts and constituents, and their input matters to legislators."

Participants formed five teams, each with an agenda of back-toback meetings with senators and representatives.

www.rls.org

In the meetings, they shared their stories and challenges of living with RLS. They advocated for support on three key issues: increasing research funding for RLS, protecting appropriate access to opioid therapy for patients with severe RLS, and expanding RLS physician education and public awareness.

Donna Rivers and her husband, Martin, traveled from Oregon to participate. "It amazed me how little most people know about RLS. I was happy to be a part of that education process," says Rivers, who volunteers as an RLS support group leader. "The experience was empowering in that I felt our plight as RLS sufferers was recognized. I believe the education provided to legislative staffers will be heard by our representatives."

Rosemary Stader, an RLS support group leader who traveled from Ohio with her husband, Gregory, says that most of the congressional staff appreciated the meetings. "I think we made a difference! The people we saw were interested; they were engaged, wrote down notes, and I think they will support our cause."

"It was win, win, win," says Julie Herbert, from Missouri. "I got to advocate for the needs for those of us with RLS, to exercise my rights as a citizen, and to spend time with some wonderfully interesting people, many of whom also have RLS, reinforcing my awareness that I am not alone. One more win: I became increasingly aware of the great work that the folks at the RLS Foundation are doing on our behalf."

"I feel like anything we do to take action with regard to our RLS gives us more strength to deal with a disorder that so often leaves us feeling frustrated and helpless," Herbert adds. "I'm so glad I went."

The RLS Foundation would like to thank all who participated in the first RLS Advocacy Day on Capitol Hill, all who joined in spirit, those who submitted letters or videos, or responded to calls to action, and those who continue to generously provide financial support for RLS advocacy efforts.

To learn more about RLS advocacy, visit www.rls.org.

## 2019 Highlights | Increase Awareness

## We're Making Progress: Let's Keep Going

#### RLS Community,

Thank you for your continued advocacy and support. In May, a delegation of RLS Foundation staff, board members and over 20 patients attended the first **RLS Advocacy Day on Capitol Hill** in Washington, DC. Our team of advocates sat down with staff of more than 45 legislative offices to educate them about RLS, share the personal stories and struggles of many of their constituents, and outline our community's unique policy considerations. This was our fourth round of meetings in DC since we launched our advocacy initiative in October 2017.

As a direct result of our advocates' hard work educating their federal representatives, Congress continues to highlight **RLS medical research** at the **National Institutes of Health** through report language in annual appropriations bills. Emphasizing the importance of funding in this area will help to move research forward, create new treatment options for patients, and bring us closer to a cure. The **Department of Defense** also continues to pursue important research activities on sleep disorders. Thanks to our community and others, Congress continued to include sleep disorders as a category eligible for funding in fiscal year (FY) 2019, and we are working to ensure the category is included for FY 2020.

We are also happy to report the impact our advocacy campaign made on the **Pain Management Best Practices Inter-Agency Task Force Report**. Over 350 RLS patients and advocates submitted comments on the report, and the RLS community's voice has been heard! Many of our concerns are reflected in the report, including an emphasis on the importance of clinical guidelines that are supported by evidence and created by organizations like the RLS Foundation that are experts in the treatment of certain conditions.

These recommendations underscore the importance of resources such as guidelines on the appropriate use of opioids for treating RLS\*, published by members of the RLS Foundation Scientific and Medical Advisory Board. We encourage you to share these guidelines with your healthcare providers to educate them on appropriate treatment practices.

In conjunction with the Task Force's report, the **Centers for Disease Control and Prevention** (CDC) has also acknowledged that its 2016 Guideline for Prescribing Opioids for Chronic Pain has been broadly misapplied, which has resulted in a loss of appropriate patient access and significant disruptions of care. The guideline is intended for primary care doctors managing individuals with chronic pain. While RLS is not a chronic pain condition, it's important to note that the guideline has contributed to a loss of access for many RLS patients who take low total daily doses of opioids to appropriately manage their RLS.

In April, the CDC published a commentary in the New England Journal of Medicine outlining ways in which the guideline has been misapplied. For example, the guideline has been misapplied to unintended groups (such as RLS patients), as well as resulted in sudden discontinuation of opioid therapy – a practice that would be potentially devastating for someone with RLS. The CDC is also working to address these misapplications through improved educational resources for patients and providers. Please visit www.cdc.gov/drugoverdose/resources for more information on these efforts.

These outcomes from the Task Force and the CDC are great steps in the right direction, but we need to keep pushing these issues forward. RLS patients across the country are still losing access to opioid therapy as a result of stigma, fear and miseducation.

Thank you again for your tireless advocacy on these issues, and your continued financial support. We will continue to update you on our progress to increase medical research, maintain patient access, and improve education and awareness.

We do this together, as always.

Sincerely,

Karla Dzienkowski, RN, BSN Executive Director, RLS Foundation

Christopher J. Earley, MB, BCh, PhD, FRCPI Chair, RLS Foundation Scientific and Medical Advisory Board

\*To view the article "The Appropriate Use of Opioids in the Treatment of Refractory Restless Legs Syndrome" and an explanatory video, visit www.mayoclinicproceedings.org.

# Webinars



<b>RLS and Depression</b> Speaker: Brian Koo, MD	December 9, 2019
SIBO and Gut Connection to RLS Speaker: Leonard Weinstock, MD	November 6, 2019
Animal Models in RLS Research Speaker: Byron Jones, PhD	October 15, 2019
What's New in RLS Research Speaker: Mauro Manconi, MD, PhD	September 5, 2019
<b>RLS Coping Strategies</b> Speaker: Norma Cuellar, PhD, RN, FAAN	August 12, 2019
<b>Congressional Visits in Your Hometown</b> Speaker: Peter Herzog	July 30, 2019
<b>Basic RLS Pathophysiology</b> Speaker: James R. Conner, PhD, MS	July 15, 2019
Medications for RLS Speaker: Michael H. Silber, MBChB	June 20, 2019
<b>Comorbidities and RLS</b> Speaker: William Ondo, MD	April 12, 2019
Managing RLS with Opioids Speaker: John W. Winkelman, MD, PhD	March 8, 2019
Augmentation and RLS Speaker: Mark J. Buchfuhrer, MD, FRCP(C), FCCP	January 24, 2019

#### **RLS Foundation Levels of Giving**

At the RLS Foundation, we rely on private donations to make our work possible. While we do receive some industry grants, our lifeblood is you and your commitment to our mission. We cannot thank you enough for the support you give every year.

**Unrestricted gifts** give the Foundation the flexibility to target funds for programs and projects that are in the most need of financial support.

**Restricted gifts** may be designated to three areas: Quality Care Centers, education and research. Donations to these funds are earmarked for special projects that may complement your intentions more closely.

**Monthly giving** allows you to spread your donation out over the year and enables us to count on a more even stream of gifts. You can also choose to restrict your gifts with this option. Monthly giving can be done by setting up a recurring credit card gift.

**Tax-deductible donations** are the quickest and easiest way to give to the RLS Foundation. Checks payable to the RLS Foundation or credit card donations completed online are fully deductible and provide an immediate source of income for programs.

**Appreciated securities** are gifts that may allow you to eliminate capital gains taxes. In nearly all cases, you are able to claim a charitable income tax deduction equal to the fair-market value of the securities, check with your tax advisor.

**Bequests** given through your estate at the time of your death are an attractive way to make sure that your interests are preserved. When you let us know about your plans to give a gift in your estate, you become a member of our Ekbom Heritage Society, an elite group at the Foundation committed to our mission and vision for the future.

If you would like to learn more about planned giving, please request our *Giving Avenues* brochure or contact us at 512-366-9109 or info@rls.org.

#### Levels

We value all of our supporters at every level. Each of you makes an important impact on the programs that help so many living with restless legs syndrome. *Thank you!* 

Leaders	\$10,000 and above
Benefactors	\$5,000 to \$9,999
Patrons	\$2,500 to \$4,999
Sponsors	\$1,000 to \$2,499
Sustainers	\$250 to \$999
Supporters	\$100 to \$249
Friends	\$75 to \$99
Contributors	<b>\$1 to \$74</b>

#### Leaders (\$10,000 or more)

Ronald and Sharon Barrett Peter and Incy Brooks Mrs. Gail S. Buckley Miss Dorothy A. Caudill Mr. and Mrs. Tommy Dunagan The Dzienkowski Family Mrs. Rhondda L. Grant Don and Alison Lovell M. Lynn McCracken Carolyn Mohn Gregory C. Oberland The Portmann Family Charitable Fund

#### Benefactors (\$5,000 to \$9,999)

Anonymous (3) James and Sandra Aberer Mary R. Burns Ms. Vera M. Gerhardt Pickett and Bob Guthrie Ann Hudson E. W. Littlefield, Jr. Ms. Catherine MacMillan Marilyn and Robert Marlette Ms. Lynda Sakraida Ms. Kay-Frances Wardrope Judy and Bob Waterman Elise & Woody Widlund

#### Patrons

### (\$2500 to \$4,999)

Anonymous Russ Buschert Ms. Barbara E. Clucas Ms. Mary Cuseo Mrs. Sue Dicristofaro J. Hunt Downing Mr. Jim B. Fullerton Charles C. Gould George Grandison Laura Scott Hoffman Janice and Larry Hoffmann Ms. Susan R. Johnson Mr. Rex E. McCrary The Mitchell Family Charitable Fund Jon & Jessica Moore Charitable Fund Mr. and Mrs. Paul Rochester The Sue Sue Charitable Foundation

Tim & Kristin Thornton Peggy R. Walker-Conner Mr. and Mrs. Cal Walstra

#### Sponsors (\$1,000 to \$2,499)

Anonymous Carolyn C. Achee Mrs. Gela Altman Mr. John Arens Guy & Dona Armstrong Ms. Barbara Bellamy Lois E. Belohlavek Lida R. Brown Lucy L. Brown Ms. Kathryn Camp Miss Heather Cornwell Lisa & Erik Cressman J. Hunt Downing Maureen Duane William J. Duane Mrs. Wanda Dzienkowski Tom Gardner Vanessa and Seth Glogower Dr. Joseph Goldston Ms. Elizabeth Grant Mrs. Gail Grim Ms. Anne W. Hammond Mrs. Delpha A. Hirth Mr. Donald Hirth Mr. Clyde L. Humphrey Mrs. Annette S. Hunter Annette & Pat Hunter Mrs. Carolyn Jester Mr. Terry Keiper Mrs. Roberta J. Kittredge Leon and Dina Krain Robert La Fountaine Mr. John L. Latham Ms. Linda L. Macey Pat & Diane McKeague Ms. Jacqueline C. Morby Morby Family Charitable Foundation Morris Family Foundation Nancy S. Passanante Mrs. Randal Peterson Starla Phelps Judy Phillips Ms. Carla Rahn Phillips Ms. Mara Rasure Mr. David T. Sands Mr. and Mrs. Stephen N. Smith PE

Mr. Freeman H. Smith III Dr. Craig Snydal Mr. Robert E. Spangler Ellen and John Spoehr Helen W. Sutphen Mr. Bernard Taylor Mr. and Mrs. John Thiele Robin Tost Mr. Aleksandar Totic Dan Vreeland Ms. Joy K. Walker Ms. Jean Wimer

#### Sustainers (\$250 to \$999)

Anonymous (21) Ms. Betty Affisco Mr. John Alexanderson Mr. Jon Allen Dr. Ronald E. Anderson Evelyn M. Anderson Dorothy Armstrong Mrs. Susan Arndt Richard C. Austin, MD Mrs. Marcia Ball Philip M. Becker, MD Lola Bermudez Inez Boettcher George and Linda Bone Mr. George Borowsky Ms. Sandra C. Bowen Mrs. Kay Bowers Dr. Kenneth Bradt Thelma Bradt Ms. Alicia Bresley Marilynn Brown Ernst B. Margee Burke Norma C. Butler Susanne Campbell Ms. Felicia M. Cashin Mrs. Patricia A. Cerny Ms. Caroline Chamales Sudhansu Chokroverty, MD Bonnie Christensen Lee C. Coates Ms. Allison W. Coleman Mrs. Rei M. Colling Dr. and Mrs. James R. Connor Mr. John Crncich Ms. Theresa A. Cullen Jonelle Prether Darr

Dr. Edward T. Dehan Ms. Helle K. DeSimone Ms. Annis Dinnerman Anne Breckenridge Dorsey Mrs. Katharine Downham Mr. Ron Draxler Helen Drewett Heyward L. Drummond, Jr. Paul B. Dudley Ms. Barbara Earnest Mr. and Mrs. Louis Echavarria Ms. Sherry Eldridge Mary Ann and Jim Emswiler Mr. Bryan Fagan Alan K. Fairchild, MD Barbara A. Faraone Mrs. Christa Fineshriber Ms. Beth Fischer Tom Flanders Emmett T. Florea Dr. Harriet Forman Mrs. Korinne Frank Mary Fransen Mr. & Mrs. Mastern Fuller Ms. Sandra Galejs Marcella Gallagher W. Peyton George Mr. Peter Gerame Mr. Jerry Gilland Mr. Chip Gillis Ms. Nina Glasner Mr. Kenneth Goodson Jr. Wayne and Donna Gregory Mr. Everett J. Grindstaff Ms. W. R. Guyton Mr. Carl F. Hagenmaier Jr. Dr. and Mrs. Matthew R. Harmody Mr. Thomas Hartzog Vic & Bettye Hauser Ms. Susanne Havlic Mrs. Lynn Hawthorne Mrs. Linda Herard Dr. Susan Hetherington Ms. Sara L. Heydari Mrs. Caren Hill Ms. Barbara Hirschy Mr. David Hoge Ms. Isabella W. Horsky Mr. Denny Hunt Mr. Peter Hunter Stephen H. Iser Ms. Sandra D. Jones

Mr. and Mrs. Hisashi Juba Mr. John Juvinall R. Fred Kautz Garry Kearns Mr. Tom Kearns Mrs. Sarah P. Kellen Mr. Darrin Kellev Mr. John Kievit Michael J. Kikta, MD Ms. Doreen Kim Dr. Marvin Kleinau Mr. Kevin Kohagen Mrs. Nancy C. Kuhn Mrs. Fave G. Kunze Mrs. Cynthia Landgrebe Walter Langford Betty Lapham Ms. Patricia A. Leighfield David A. Lewis Mrs. Lee Lipman Mr. & Mrs. Charles F. Lipscomb Dorothy Liston Paul Lohrenz Mrs. Barbara Mack Ms. Susan Mallory Mr. and Mrs. J. Terry Manning Ms. Christina Marciniak Mr. and Ms. William Marietta Mr. Harry Masters Mr. Steven McCann Mrs. Grace McCartin Mr. Patrick McIlrath Linda McKenna Marney Mesch Mr. Eric Moen Ms. Karen Mokrzycki Dr. Frits Mooi Martha Mowrer-Urban Mrs. Diane P. Moyer Roger Mulvihill Dr. Daniel J. Murphy Jim & Barbara North Mr. Peter Nostrand Ms. Nancy K. Olson, RN Mr. William Pattinson Mr. Robert J. Peroni Mrs. Peggy R. Peterman Dr. Matthew Petrie Lewis M. Phelps Mr. Stephen Plattus Mr. Gary Pollatz

Ms. Debra B. Price Ms. Bettina Proctor Ms. Janet Prueitt Mr. Mark Quinton Mrs. Betty J. Quist Dr. Rollin J. Randall Mrs. Joyce Ratkowski Mr. Walter H. Rauser Darvl and Ella Reid Chris & Sheila Richards Nancy Ritchie Ms. Kathryn W. Roberts Mr. Lawrence Rockwood Mr. Mark Rusley Ms. and Mr. Sue Sabaloni Ms. Rachel Sanders Ms. Sonnhilde Saunders Ms. Helen T. Schauer Mrs. Elizabeth O. Scheben Lori Schifrin Ms. Susan Schlichting Jan Schneider Mr. John Schwager Mr. Allen Secrest Linda Secretan Mr. Allan Segel Mrs. Diane Segel Mr. and Mrs. F. R. Sekowski Mr. Daniel G. Shoaf Frances Cain Slote Dwain L. Smith, DVM Michael & Regina Spaulding Mr. Monty Stephen Ms. Mary Stompe **Jack Stone** Mrs. Constance Stoner Ms. Doris B. Stretch Ms. Alida D. Sullivan Mr. Timothy Swanson Ms. Dale Talley Mr. Stephen L. Tate Mr. William Tellefsen Grant P. & Sharon R. Thompson Mr. John Trefethen Lynn Marie Trotti, MD, MSc Mrs. Jan Tschantz Mr. Thomas E. Turk Jr. Mrs. Wendy Veiga Mrs. Eileen Vermillion Ms. Patricia Veuve Ms. Joan Voigtlander Marguerite H. Wagner Christine Tunison Wait

Karen Walborn Laura Walker Mr. Jon Wellinghoff Mr. and Mrs. Eugene Wendt Ms. Sheila Wengert Leah R. Wickham Mr. Tom Wieker Ms. Marilyn Wilkes Mr. Paul Witkowski Diane W. Wood Ms. Toby Woodhouse

#### Supporters (\$100 to \$249)

Anonymous (35) Mr. Mark Abramovic Anne Adams Gorry Ms. Carole Adams Mr. Jesse Adams Mr. Jay D. Adkisson Mr. William Ahern Mrs. Karon Ahrendt Mrs. Elizabeth Albert Mr. Arthur Alberts Mr. and Mrs. Ralph L. Albright Ms. Melba Alderman Ms. Paije Alfano Jean A. Allee Serena Alleman Janet L. Allis Mrs. Harriet Anani Gavle V. Anderson Dr. John H. Anderson Jr. Mr. & Mrs. Leland E. Anderson Mrs. Mary F. Anderson Mrs. Patricia Anderson Ms. Paula Anderson Mr. Craig Ankerstjerne Estelle Anstett Mr. Jack Antolak Mr. Donald Arbuckle Larry L. Arndt Ms. Joan Arsenault Ms. Carole S. Arthur Mr. Donald N. Babb Mrs. Janet Bailey Mrs. Patricia M. Bailey John W. & Mary C. Baker Mrs. and Mr. Mary C. Baker Ms. Mary Ellen Baker Mrs. Nancy Baker

Mrs. Jacqueline Baratian Ms. Christie Barbour **Bob Barker** Mr. Rich Barra Ms. Agnes R. Barrett Mrs. Marjorie Barry Mrs. Carol Bates Mr. Donald T. Becker Ms. Pamela D Becker Ms. Phyllis Beery C. F. Beil Stephen Belanger Carl G. Belk Mr. Richard Bell Joanne Bellan Darleen Bennett Ms. Diane Bennett Mr. Leonard Berger Mr. Paul H. Bergh Mr. Gerry Berglin Barbara Berrier Mrs. Margaret Berwanger Elizabeth L. Bewley Mrs. Vinnie Biberdorf Mr. Richard Billings Ms. Henry Birnkrant Mrs. Diana Bjel Mrs. Barbara Blahuta Mr. Joseph Blanchette Mrs. Carol Blaschke Mrs. Marianne Blilev Mr. Paul T. Blizzard Ms. Janet Blocker Ms. Catherine M. Boehme Ms. Susan Boehme Mr. Steven Boerma Mr. Jeffrey Borofsky Mr. William Bossenberger Ward C. Bourn Carolyn P. Bower Dr. Dolores A. Bower Mr. John Bowman Ms. Carol Bradford Nancy Bradford Mr. Bruce Bredland Dr. & Mrs. James Breece Mr. and Mrs. Clark Breeze Ms. Carol Bretta Mr. Arnold A. Brewer Mr. Frank Bright Mr. Clarence Brink Ms. Betty M. Brockington Ms. Julie Brook Mr. David Brown

Iane E. Brown Ms. Susan Brown Robert and Lenore Brugger Mr. Terry Bruton Katherine Bufanio Mr. Nicholas Bulthuis Mrs. Judy Bunkall Mr. William Burch Mr. Leonard Burden Ms. Mary Lou Burket Mrs. Mary Burnette Colleen A. Burroughs Ms. Becky Butler Mr. William L. Byrd Mrs. Martha Calder Ms. Carol Calkins Ms. Bonnie Campbell Ms. Margaret Campbell Mr. Dave W. Candler Mr. Al Capitanini Ms. Joann Carnes Mr. Paul A. Carney Ms. Bonnie M. Carroll Ms. Mary Lou Case Mr. Nick Cavarocchi & Mrs. Bridget Cavarocchi Ms. M Corinne Chafey Mr. Paul Chalkis Mr. John Champ Mrs. Kitty Champlin Dr Roxana Chapman Ms. Vera Chernoff Dr. Cheryl Child Ms. Laura E. Childers Mr. Ron Cicchini Mr. Thomas R. Clem Sr. Mr. Donna E. Clifford Mr. Thomas Coco Annebelle J. Cohen The Columbus Foundation Mr. and Mrs. David Conger Mrs. Patience Conley Mr. George Connell Sheila C. Connolly Mr. Michael C. Connor Mr. Charles Cooke Mr. and Mrs. Clive Cook Mrs. Joanne Correll Mrs. Debbie Costa Mr. Richard Costello Jr. Ms. Suzanne Covert Mr. John Cox Ms. Barbara Crain Elizabeth Crawford

Mr. Roger Crooks Mr. Dennis Crouch Mrs. Lois M. Crouch Patrick Crowlev Mrs. Dorothy Cummings Ms. Kita Curry Samuel D'Amato, MD Susan Dabelsteen Ms. Yvon Dacavana Mr. Frank Dajka Mrs. Jeanne M. Dallas Io Dalv Mr. Jonathan Damonte Ms. Trudy K. Dana Ms. Sidney Daniel **Jim Daubenmier** Mr. Bruce H. Davidson Mrs. Elaine F. Davis Ms. Suzayne W. Davis Ms. Cari Dawson Mrs A. Jean De Hart Wilma De Jong Ms. Barbara Dean Mr. William Deisher Mr. William Deloach Mrs. Cindy Denico Mr. Ronald DeRuiter Ms. Helgard Deuel Ruth DiBella Mr. Charles Dickinson Mindy and Joe Dill Mrs. Diane Dillenbeck Ms. Kathy Dimiduk Ms. Dee DiPiero Elizabeth Dirkx Ms. Jeanne Donie Mrs. Karen Doughan Mr. James Dougherty F. Edward Dudek Paul H. Dudek Mrs. Ellen Duffy Mr. Bill W. Duncan Mrs. Deborah Early Mr. Lorne L. Ebel Ms. Diane Edell Ms. Mary K. Edwards Mr. Peter Edwards Mrs. Reba Eich Ms. Carolyn Elbon Joan Elder Mr. Douglass Ell Roberta Elliott Vashti P. Elliott Mr. Brent Elphick

Ms. Phylis Elsing Mrs. Sylvia Ely Dr. and Mr. Dorothy Emerson Michael J. Enright Mrs. Laurel Euler Ms. Janet Evans Mrs. Diane M. Evasick Mr. John Everton Mr. Robert Ewart **Richard Ezell** Dr. Joe Fagan Mrs. Pam and Rob Fairly Mr. Sigo Falk Ms. Eileen T. Farley Win Farquhar Ms. Anne-Marie Farrell Ms. Lisa Feinstein Ms. Lori Finger Marsha S. Firestone Mr. Eugene Firmine Lee J. Fischer Mrs. Merial R. Fitzgerald Don and Carol Flammer Mrs. Diane Flatley Mrs. Sue Fletcher Mrs. Therese Flingos Elmer G. Foley Mr. Ted Foreman Ms. Linda G. Fors **Evelyn France** Mr. John Frieden Ms. Karen S. Fulks Mr. Foster Furcolo Jr. Dr. Julia Gaff John D. Gage Mr. David Gagne Mr. Hamilton A Gale and Mrs. Bonnie V. Gale Ms. Sylvia R. Gallagher Mrs. Norma Galusha Mr. Art Garman, Jr. Debra L. Garner Jeannine Garrett Mr. Joseph S. Gass Carolyn Geduld Mr. Jay Gerard Ms. Elizabeth Germain Kenneth E. German Thomas Giampino Miss Lucynda Gibbs David Gilbertson Ms. Tracy Gilchrist Mrs. Debbie Gill

Ms. Marion E. Gillen Mr. George M. Gingerelli Mr. Ike Glass Ms. Ellen Glatter Mrs. Polly Glavine Ms. Catherine Glowacky Mrs. Ruth A. Goats Mr. Doren Goldstone Mr. Robert Gorecki Ms. Mary Gossett Mr. James Gould Erica Grantmyre Dr. Steven E. Graves Mrs. Mary Grecco Sharon J Green-Hennessy, PhD Mr. Neil Greenwood Mrs. Diane Grefer Mr. Jerald Griffin Mrs. Maxine Griffin Ms. Suzan K. Griffin Mr. Donald Griggs Ms. Valerie L. Grosch Mr. John Grummitt Mrs. Shiras Guion James A. Guldan Ms. Patricia Gundrum Ms. Janet Gunther Douglas and Marcia Haas Mrs. Edith T. Hackman Mrs. Carolyn M. Hahne Dr. Iudith Hall Mrs. Richard Hallock Dr. Ann Hallum Donald and Mary Ann Hamman The Handley Foundation Mr. Stephen L. Handley Dr. Paul Hansma Ms. Elizabeth H. Hardison Mrs. Mary Jo Hardy Jeff and Pam Harms Mrs. Shervl Harris Mrs. Kimberly Harris Mr. Burlin C. Harrison Georgia G. Hart Ms. Marianne Haug Ms. Karen Hawkins Jim Healev Donna Heaney Mr. Carl Heintzelman Mr. Stephen Henderson Dr. Kevin D. Hennessy Jennifer G. Hensley EdD, CNM, WHNP

Mrs. Julie Herbert Mrs. Dolores Hermann Mr. Gilbert Heth Ms. Gail Hill Mr. John D. Himmelfarb Mr. Matthew Hinerfeld Mrs. Tina Hines Robert Hirth Mr. Llovd Hittle Mr. Lafloyd H. Hobbs Ms. Connie Hodge Patty Hodgins Mr. Stanley Hoernicke Donald E. Hoffman **Judith Hoffman** Dr. and Mrs. Dean G. Holland Mr. Peter K. Hoover Mr. Ron R. Hopperton Joan Hudgins Mr. Bonnor E. Hudson III Mr. James S. Huffman Mr. Mickey C. Hurry Thomas D Hurwitz MD Jean Hayden Hutchins Jacquelyn C. Hutson Lucille L. Hynes Ms. Willemien Insinger Mr. Paul V. Irvine Susanne Isbill Mr. David Ivers Mrs. Cleo P. Jackson Mrs. Marie James-Roane Mrs. Maureen Janda Glenn W. Jeffrey Mrs. Audrey Johnson Ms. Catherine Johnson Mr. Frank Johnson Mrs. Patricia A. Johnson Mrs. Peggy Johnson Mr. David J. Johnston Mrs. Evelyn Johnston Mrs. Anne Markey Jones Mr. Bob Jones Elizabeth R. Jones Ms. Judy Jongsma Mr. James Joyce Ms. Glenda Jutson Mr. Edward Kalinowski Ms. Joyce S. Kallaher Ms. Dianne Kanzler Anoop Karippot, MD, DABSM Mr. Ken Kaser

Ms. Sandra Katanick Mrs. Linda M. Kawtoski Ms. Leslie Kean Mrs. Judith Keeling Ms. Patricia Keller Mr. Henry Kelly Mr. Paul M. Kelly & Mrs. Lynne T. Kelly Mrs. Caroline Kennedy Dr. Nicholas Kentopp Mr. Benjamin (Eileen) Keppler Ms. Nora Kerr Allan R. Kerze Mr. Kaled Khaznehkatbi Mr. Patrick J. King Ms. Mary King Ms. Patricia Knote Ms. Kathryn Koch Mr. Robert Komenda Leo A. Kominek Rosemary Kosmak Kathleen Kotchi Dr. Mark Kozlowski Dr. Glenn Kreielsheimer Dr. Laurence Krieg Mr. Michael Kun Sandra Kussin Mr. Brian Landsberg Mr. John Lane Mrs. Rae Lapides Ms. Kim Larrow Ms. Nancy Lauby Mr. Michael T. Lavelle Ms. Catherine Lawson Mr. Roger Leflour Mr. John Lehmann Peg Lenz Mr. Scott R. Levad Nan Levorsen Mr.& Mrs. Leon Levy Amelia Lewellen Mr. Robert Lewellen Mr. William Lewis Jr Mrs. Maureen A. Lightbody Mr. Gerald J. Lillquist Gary and Barbara Lind Mrs. Rebecca Lindberg Dr. Christine Linder-Skach Ms. Emily Lobatto Eileen S. Lorenz Mr. Everardo Luchetti Mark D. Luedke, MD Ms. Rhonda Luedke

Ms. Jean L. Mabie Mr. Richard Machalek Tom Mack Mr. Kenneth F. MacKay Colin MacKenzie Tom E. Main Mr. Frank Malacane Ms. Saida S. Malarney Mrs. Tove Mandigo Ms. Mary H. Manning Mr. Charles Marcous Mrs. Earlene Margetts Carol Mayer Marshall Mr. Rob Marshall Ms. Susan Marshall Mr. David Martens Mrs. Debra Martin Ms. Chervl Masters Mr. Edward Matkins Rev. James & Jean Matthews Marcia Matthieu Alice Maxin Mr. Kevin B. May Mrs. Kay McCargar Mrs. Elaine McDonald Mrs. Janet McFadden Mr. Robert McIntyre Mrs. Patricia McKee Ms. Teri McMahon Christine McMorrow Ms. Karen L. Mendonca Mr. and Mrs. Vincent Mennona Charlene R. Mentink Ms. Kathryn Meredith M. Marjorie Meredith Mr. Larry Michals Elsa Michitsch Mrs. and Mr. Carol E. Miller Mr. Douglas Miller Mr. Herbert Miller Ken Miller Sally Mills Mrs. Ida R. Minor Mr. Darius Mistry Stephen W. Mixon Ms. Joyce Miyasato Ms. Clydeen Moller Ms. Marilyn H. Molloy Judy C. Monostory Mr. Robert Montcalm Diane M. Moore Donald T. Moore Nellwin E. Moore

Mrs. Solveig Moore Robert L. Morissette, PhD Donna M. Morrill Mr. Kent Mortensen Ms. Linda Morton Steve Morton Mr. Charles Moyer Ms. Gale Munson Mr. Edward Murphy Susan Murphy Walter W. Murrell, PhD Mr. Felix Nadeau Dr. Jerold Needelman Ms. Barbara J. Nelson Mr. and Mrs. Larry D. Nelson Dr. Sue Nelson Ms. Tess Nelson Mr. Kent Newmark Ms. Mary Nolan Mrs. Mary Payne Norcross Mr. Arlo R. Nord David S. Nourok, MD Keith and Bonnie Noyes Mr. Paul Nozick Ms. Virginia P. Nurco Ms. Diane O'Connor Mrs. Barbara Odenkirk Ms. Carol M. Ogrodnik William G. Ondo MD Ms. Bette Oswell Mr. James Painter Mr. Ron W. Panter Mr. Raial Patel Mrs. Carolyn K. Pater Mr. Robert Patterson Robert J. Patterson Mrs. and Mr. Anne Patton Mr. Thomas N. Pearson Sr Ms. Cynthia Pearson Donna S. Peckinpaugh Mr. Dana Peckworth Ms. Maureen Pedzwater Ms. Mary Lou Pelzer Ms. Judy Penniman Lorys Penrod Mrs. Kathleen Perricelli Donald L. Perry Joyce Perry Dr. G. Peters Mrs. Donna R. Peterson Ms. Danna J. Pettigrew Ms. Maureen Phillips Mr. Gary Pirko

Ms. Suzanne Pirko Mrs. Karen Podges Mr. Robert L. Poff Mrs. Carolyn Poindexter Mr. Anthony Polifronio Mr. Bruce Pollack Mr. Ross Pollock Jacquie Powell Ms. Kave Powers Mrs. Christina M. Price Dr. Stephen N. Price Mrs. Ruth Prim Elizabeth Purcell Mr. and Mrs. Stanley Quade Mrs. Carolyn Quick Mr. Thomas Rader Ms. Barbara J. Ragland Ms. Janice Anne Ramsay Mrs. Jackie Ramsever Mrs. Peter L. Randlev Ms. Sharon Rask-Huntington Ms. Patricia Rathke Carey Rayce Mr. Robert W. Read Mrs. Martha H. Rediehs, RN, MSN Mr. Martin Redman Mr. Robert Reese Ir Mrs. Diane M. Reinhart Mrs. Karen Remick Joyce E. Richardson Roberta M. Richardson, MD Mr. Johnnie Ricketts Laura and Patrick Riley, MD Mr. Jay Riojas Ms. Donna Rivers Carol Roberts Ann Robertson Jean Robertson Ms. Carroll Robinson Thomas A. Romig Ms. Constance Rosenberg Mrs. Janice Rottman Richard Roullard Claudia A. Ruzanic Ms. Kay Sable Kei Sakita Mrs. Linda T. Salzman Mr. Curtis Sanders Mrs. Linda R. Schaeffer Mrs. Shirley L. Schapler Mrs. Isabel Sonia Schneider Mrs. Jeanne Schoedinger

Ms. JoAnn E. Schoenegge Ms. Donna M. Schroeder Mr. and Mrs. Roger C. Schulte Ms. Karen Schwager Mr. Stuart Schwartz Mr. Martin Schwirzke Mr. Douglas Scott Jack T. Scully Mrs. Joan Seeberger Carol J. Seely Donald Semrau Shirley I. Seymour Louise Sharp Mr. Gerald Shea S. I. Shedenhelm Ms. Carmen Shell Mrs. Eleanor Mary Sheridan Mrs. Carroll Shipley Mr. Dennis Sienicki Michael H. Silber, MB, ChB Dr. Ronald Silvestri Mr. Michael Simko Dr. Omar Skalli Ms. Patricia Skillman **Delores** Slawik Mr. David Slay Mrs. Jane Sleight Mrs. Mary E. Sloan Mr. Terry Smedley Mr. Duncan M. Smith Mr. Gregory Smith Mr. Jim Smith Mr. and Mrs. Michael K. Smith Preston L. Smith Mr. Ronald J. Smith Russell Smith Mary Ellen Snively Ms. Jacqueline A. Snodgrass Mr. Henry G. Solomon Mrs. Patricia Spampinato Mr. Richard Sparling Ms. Beula J. Spell Mrs. Hannelore M. Spence Ms. Susan Spengler Mrs. Joyce C. Spivey Ms. Susan Spring Dr. James Sproul Kermit Spruill Sheila A. Stankus Mrs. Judy M. Staples Mr. Jon Stasney Mr. Eric Steeg

www.rls.org

Ms. Jacqueline N. Steensma Mr. Jim Stein Mrs. Faye M. Stephen Mrs. Gwendoline Stewart Mr. and Mrs. Marshall Stivers Ms. Jill E. Stolpestad Joe M. Stovall Mr. Robert T. Stover Mr. Richard Straub Harriet T. Strong Ms. Jean Strouf Mr. Joseph Suchecki Mr. Tom Sullivan Mr. Jerry Sussman Nan Suydam Ms. Pamela Swain Marian W. Sweeney Ms. Susan Swigart Mr. James G. Swope Ms. Kathleen Taube Harry C. Taylor Janice Taylor Mrs. Sarah Terhune Mr. Andrew T. Tershak Susan Theiss Mrs. Clara Thomas Mr. Tim M. Tierney Barbara Torell Ms. Alejandrina Torrens Mrs. Ruby Townsend Mr. Melvin G. Trammell Ms. Janet L. Trent Ms. Carol Turkaly Mr. James Turner T. Michael Ulwelling Dr. Gary Utz Ms. Mary Valiant Mr. and Mrs. Robert Van Etten Ms. Elizabeth VanderBurg Patricia Vavrick Ms. Shirley Veach Mr. Richard Vezza Mr. Robert Visser Mr. Steven Vogel and Ms. Jane Henderson John M. Wadahara Kate Wagner Ms. Judy Wagnitz Ms. Stephanie Waldhart Gordon Waldron Mr. Gary Walker Mrs. Shirley M. Ware Mrs. Mary Ann Watrous

Mr. and Mrs. Lawrence P. Watson Mr. Rupert Watson Kit Weinschenk Ms. Nanci Weissgold Ms. Victoria Welch Mr. Bill Wendt Mrs. Mary Wendt Sheila C. Wheatley Mr. Stephen White Ms. Carolyn Wilcox Ms. Deborah Wilcox Mrs. Diane R. Wilds Dr. Keith D. Wilkinson Mr. Kent Williams Larry and Fran Williams Ms. Laurena Williams Ms. Donna Willis Ms. Caroline R. Willms Judy Willoughby Ms. Naomi Wilson Mrs. Ruth Wixted Mary Lou Wohlhieter Mr. Eduard Wojczynski Mrs. Lucy H. Wong Ms. Barbara Wood Mr. Gerald Wood Mr. Gordon Woodard Mrs. Julia Woodward Mr. Cody Wray Mrs. Anita Wright Mr. Des Wytmans Ms. Lois Yarbor Mr. Ted Yednock Mrs. Alice B. Yoakum Mr. Sheridan Young Mr. William Young Mr. Joseph Zabreznik Ms. Ann L. Zimmerman Barbara Zizka Mr. Mel Zoerb

## **Treasurer Report**



Ron Barrett, PhD Treasurer

I would like to thank the members of the RLS Foundation for their continued support and commitment to the RLS Foundation during our 2019 fiscal year. Individual donations comprise most of the financial support for Foundation programs and activities, representing 77% of total revenue to the organization.

In fiscal year 2019, the Foundation continued to support the mission and organizational goals of awareness, education, and research to find a cure. Members of our Scientific and Medical Advisory Board reviewed and updated our library of educational materials to educate the general public and medical community about RLS. These volunteers served as presenters in our monthly webinar series and the healthcare provider only webinar series aimed at educating the medical community about the diagnosis and management of patients with RLS. Our educational outreach continues through information posted to the Foundation's website and social media channels including Facebook, Twitter, Instagram, YouTube, and LinkedIn to reach RLS sufferers and their healthcare providers. Volunteers that lead our support groups and discussion board provide individuals with RLS the opportunity to exchange information and coping strategies with others who live with the daily challenges of RLS. The RLS Foundation's acclaimed quarterly magazine, *NightWalkers*, provides members with in-depth stories about RLS Foundation funded research, and information regarding promising research and treatments available today. These diverse channels provide the Foundation access to a broad audience of individuals with the disease, fulfilling our mission to provide knowledge and raise awareness of RLS.

The second and third components of our mission are to support the development of improved treatments and a cure for RLS. The Foundation has provided an additional year of funding for a multi-center longitudinal pilot observational study of the efficacy and tolerability of long-term use of opioids as a treatment for RLS. Information from this study has enhanced the Foundation's advocacy efforts to assure that any legislative and policy regulations to address the opioid epidemic do not negatively impact the medically necessary use of opioids by individuals with refractory RLS. A second grant was funded to study how opioid medications work in the brain to relieve RLS. The aim of this study is to discover why this class of medication is effective in treatment of RLS and could lead to new non-opioid drug development.

The RLS Foundation advocacy program helped to raise the profile for RLS in Washington DC. In 2019, the Foundation conducted the first RLS Advocacy Day on Capitol Hill. The RLS Foundation delegation met with key legislative offices to seek additional research funding for RLS, seek a safe harbor for RLS in any policy or legislation and expand awareness and physician education. Members, like you, make these advocacy efforts possible through your generous support.

The RLS Foundation's Finance and Audit Committee reviews and recommends for Board approval the budget for the upcoming fiscal year. Throughout the year, the Committee monitors revenue and expenditures of the Foundation and then oversees the annual audit performed by an independent accounting firm. This financial oversight ensures donations and other foundation income are spent on programs beneficial to the members of the RLS community.

It has been my pleasure to serve you as Treasurer during the 2019 fiscal year. I look forward to our continued work together and the future success of the Foundation in 2020!

Sincerely

RALWRS

Ronald W. Barrett, PhD

## 2018 Highlights | Financials

#### **Revenues and Support**

Contributions	\$612,710
Membership Dues	\$163,562
Other	\$15,509
Total revenues and support	791,781

#### **Expenses**

Program Services	
Education	\$370,836
Membership	\$206,650
Research	\$83,266
Support Groups	\$28,119
Total program services	\$688,871
Fundraising	\$83,597
Management and general	\$69,889
Total expenses	\$842,357

Statements of Activities For the Fiscal Year Ended September 30, 2019


:

The RLS Foundation's full financial statements, the complete audit opinion of Reynolds and Franke, PC, CPA, and all accompanying notes are available online at: www.rls.org

:

#### 2019 Where Our Funds Come From

#### 2019 Where We Use Our Funds



Education and awareness	44%
Membership	25%
Research	10%
Fundraising	10%
General and administrative	8%
Support Groups	3%

# RLS Community Speaks Out





3006 Bee Caves Road Suite D206 Austin, TX 78746

512-366-9109 info@rls.org

www.rls.org rlsfoundation.blogspot.com Discussion Board: bb.rls.org

